logo
Juice Recall Update As FDA Issues Highest Risk Warning for 12 States

Juice Recall Update As FDA Issues Highest Risk Warning for 12 States

Newsweek25-04-2025
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Juice recalled over potential harmful bacteria contamination has been issued a Class I risk warning by the Food and Drug Administration (FDA).
Walker's Wine Juice LLC of Forestville, New York, recalled its pumpkin juice on March 28 due to possible contamination with Clostridium botulinum, a bacterium that can cause botulism, a serious illness that affects the nervous system.
The product was distributed in 12 states, including Illinois, Indiana, Kansas, Kentucky, Maine, Michigan, Minnesota, New Jersey, New York, Ohio, Pennsylvania and Wisconsin.
Newsweek has contacted Walker's Wine Juice for comment.
Walker's Wine Juice LLC recalled its pumpkin juice on March 28 due to possible contamination with Clostridium botulinum.
Walker's Wine Juice LLC recalled its pumpkin juice on March 28 due to possible contamination with Clostridium botulinum.
Andreas Franke/Sebastian Kahnert/DPA/AP
Why It Matters
Botulism, a potentially fatal form of food poisoning caused by Clostridium botulinum, can cause a wide range of symptoms including general weakness, dizziness, double-vision and trouble with speaking or swallowing.
It can also cause difficulty in breathing, weakness of other muscles, abdominal distension and constipation.
According to the FDA, around 10 outbreaks of foodborne botulism occur annually in the U.S.
What To Know
The affected products were packaged in 2.5- and 5-gallon boxes, along with 30-, 60- and 275-gallon bulk containers.
All lots and codes of the product were included in the recall, and the FDA said that a total of 1,466 gallons of juice were affected. According to the FDA, the recall is still ongoing.
As of April 1, no illnesses had been reported, Walker's Wine Juice said.
The FDA issued its Class I risk classification on April 222, meaning it is a "situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death."
The potential contamination was discovered after inspectors from New York's Department of Agriculture and Markets found that the pumpkin juice pH was too high for the "hot fill" process to be carried out effectively when being packaged.
The FDA said that is was subsequently determined that "no adequate kill step was used to address the possibility of microbiological hazards."
What People Are Saying
The World Health Organization said on its website about botulism: "Foodborne botulism is a serious, potentially fatal disease. However, it is relatively rare. It is an intoxication usually caused by ingestion of potent neurotoxins, the botulinum toxins, formed in contaminated foods. Person to person transmission of botulism does not occur."
The FDA wrote in a report on the bacteria: "A food may contain viable C. botulinum and still not be capable of causing botulism. If the organisms do not grow, no toxin is produced. Although many foods satisfy the nutritional requirements for the growth of C. botulinum, not all of them provide the necessary anaerobic conditions. Both nutritional and anaerobic requirements are supplied by many canned foods and by various meat and fish products. Refrigeration will not prevent growth and toxin formation by nonproteolytic strains unless the temperature is precisely controlled and kept below 3°C. Foods processed to prevent spoilage but not usually refrigerated are the most common vehicles of botulism."
What Happens Next
Walker's Wine Juice LLC has warned any consumers experiencing symptoms related to botulism to seek immediate medical attention.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rybelsus Medical Weight Loss Program
Rybelsus Medical Weight Loss Program

Time Business News

time5 minutes ago

  • Time Business News

Rybelsus Medical Weight Loss Program

Losing weight can be one of the most challenging goals a person faces. Despite efforts with diet and exercise, many find it difficult to shed excess pounds or keep the weight off long term. At Family Medical Centers, we offer a medical weight loss program that includes innovative treatments like Rybelsus, designed to help you succeed in your weight management journey. For many, weight loss isn't just about appearance—it's about improving overall health and reducing risks related to obesity, such as diabetes, heart disease, and joint problems. Sometimes, diet and exercise alone don't provide enough support. Medical weight loss programs step in to fill this gap, combining expert guidance with proven medications. Rybelsus, a medication containing Semaglutide, is part of this modern approach. It supports the body's natural systems that regulate hunger and metabolism, making weight loss more achievable and sustainable. Rybelsus is an FDA-approved oral medication originally developed to treat type 2 diabetes. It works by mimicking the hormone GLP-1, which helps regulate blood sugar and appetite. By activating GLP-1 receptors, Rybelsus helps reduce hunger, slows digestion, and improves insulin sensitivity. This unique combination means people using Rybelsus often feel fuller longer and eat less, which supports steady weight loss when paired with lifestyle changes. The active ingredient, Semaglutide, acts on GLP-1 receptors found in the brain and digestive system. This action helps: Reduce appetite by affecting hunger signals Slow gastric emptying, which prolongs feelings of fullness Enhance insulin response, improving blood sugar control These benefits work together to make it easier for patients to maintain healthy eating habits and lose weight effectively. At Family Medical Centers, weight loss treatment is never one-size-fits-all. Our team designs personalized plans tailored to your health status and goals. If Rybelsus is suitable for you, it will be integrated alongside nutrition counseling, physical activity guidance, and ongoing medical supervision. The program includes: A thorough initial health evaluation Customized diet and exercise plans Medication management and education Regular progress reviews and support This comprehensive method helps patients achieve lasting success. Clinical research shows that Rybelsus users can experience meaningful weight loss, especially when combined with healthy habits. Key benefits include: Noticeable weight reduction, especially in individuals with a higher BMI Improved blood sugar regulation and metabolic health Better appetite control leading to reduced calorie intake Assistance in maintaining weight loss long-term Together, these advantages make Rybelsus a valuable tool in the fight against obesity. Starting Rybelsus involves working closely with your healthcare provider to find the right dose and monitor your response. Many patients experience reduced hunger and slower digestion early on, which naturally helps with portion control. Side effects can include mild nausea or digestive discomfort, but these typically improve as your body adjusts. Regular follow-ups ensure your plan remains safe and effective. We know that weight loss is deeply personal and can be influenced by many factors including genetics, lifestyle, and medical history. Our care team is dedicated to providing ongoing encouragement and adapting your plan as needed. By combining Rybelsus with individualized coaching and medical oversight, Family Medical Centers helps patients overcome barriers and build healthier, sustainable habits. Can I take Rybelsus if I don't have diabetes? Yes, Rybelsus is now commonly prescribed for weight management even in individuals without diabetes. How quickly will Rybelsus help me lose weight? Results vary, but many patients notice appetite changes and weight loss within weeks. Are there risks or side effects? Side effects are usually mild and may include nausea or stomach upset. Your healthcare provider will monitor you closely. Will I need to stay on Rybelsus forever? This depends on your individual health and weight goals; your provider will help determine the best course. Is lifestyle change necessary when taking Rybelsus? Yes, combining Rybelsus with healthy eating and exercise yields the best results. Weight loss is rarely simple, but with the right support, it's achievable. Family Medical Centers offers a caring, personalized program that uses modern tools like Rybelsus to assist your journey toward a healthier life. TIME BUSINESS NEWS

FDA Report: Synthetic 7-OH Products Pose Severe Opioid Risks
FDA Report: Synthetic 7-OH Products Pose Severe Opioid Risks

Associated Press

timean hour ago

  • Associated Press

FDA Report: Synthetic 7-OH Products Pose Severe Opioid Risks

Agency finds 7-OH products lack safety data, carry high abuse potential, and risk respiratory failure The Stop Gas Station Heroin coalition today applauded the U.S. Food and Drug Administration's release of a new report, " 7-Hydroxymitragynine (7-OH): An Assessment of the Scientific Data and Toxicological Concerns Around an Emerging Opioid Threat.' Its findings confirm what public health experts have long warned: Concentrated 7-OH opioid products are not natural kratom, but highly addictive synthetic opioids that put American consumers at serious risk. The FDA's Center for Drug Evaluation and Research (CDER) found that: '7-OH isn't a wellness product; it's a synthetic opioid,' said Dr. Nicole Avena, research neuroscientist and expert in addiction. 'The FDA's findings reinforce what we've seen clinically — these products carry real risks of dependency, overdose, and long-term harm. Selling them as dietary supplements is misleading and dangerous.' The FDA report also notes that results across multiple independent studies align: Preclinical addiction models show the high-risk profile of concentrated 7-OH, making it clear that these substances should not be marketed directly to consumers. Despite being packaged as 'natural' remedies, concentrated 7-OH products are chemically manufactured drugs that are illegally sold without FDA approval. Some are branded as pain relievers or treatments for opioid withdrawal despite lacking any clinical proof of safety or effectiveness. 'Objective science has spoken,' added Avena. 'Concentrated 7-OH opioid products are illegal, unapproved new drugs. Until companies produce peer-reviewed clinical research and secure FDA new drug approval, these products must be kept off the market to protect American families.' About Stop Gas Station Heroin Stop Gas Station Heroin is a national coalition that aims to educate consumers about harmful synthetic drugs and advocate for smart regulation that distinguishes between legitimate, natural botanicals and dangerous, synthetic drugs, combined with enforcement of current federal laws around unapproved drugs. To learn more, navigate to Media Contact Media Contact [email protected] ### SOURCE: Stop Gas Station Heroin Copyright 2025 EZ Newswire

Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ...
Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ...

Yahoo

time2 hours ago

  • Yahoo

Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ...

Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Inovio Pharmaceuticals Inc (NASDAQ:INO) is on track to submit its BLA for INO 3,107 in the second half of 2025, with the goal of file acceptance by year-end. The company has completed the design verification testing of its Selecttra 5 PSP device, a key milestone for regulatory progress. INO 3,107 has been granted breakthrough therapy designation by the FDA, allowing for a rolling submission of the BLA. Clinical data from INO 3,107 has been published in reputable journals, supporting its potential as a preferred treatment for RRP. Inovio Pharmaceuticals Inc (NASDAQ:INO) has significantly reduced its operating expenses by 31% year-over-year, demonstrating fiscal responsibility. Negative Points Inovio Pharmaceuticals Inc (NASDAQ:INO) experienced a decrease in cash equivalents and short-term investments, from $94.1 million at the end of 2024 to $47.5 million by mid-2025. The company anticipates an operational net cash burn of approximately $22 million for the third quarter of 2025. There is uncertainty regarding the potential need for an advisory committee meeting for the BLA submission, which could impact timelines. The company faces competition from other treatments in the RRP space, which could affect market share and enrollment in confirmatory trials. Inovio Pharmaceuticals Inc (NASDAQ:INO) has not provided specific guidance on the size of its commercial organization, which may impact its ability to effectively launch INO 3,107. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with INO. Q: Are you anticipating having an advisory committee meeting for the BLA submission of INO 3,107? A: Dr. Mike Sumner, Chief Medical Officer, stated that based on interactions with the FDA, there has been no indication that an advisory committee meeting will be necessary. The overall risk-benefit data presented does not suggest a requirement for such a meeting, although the final decision rests with the agency. Q: How does the upcoming regulatory decision for a competitor affect Inovio's launch plans for INO 3,107? A: Dr. Jackie Shea, President and CEO, highlighted significant differences between Inovio's program and the competitor's, including trial design and technology. Inovio's focus is on a placebo-controlled confirmatory trial, and the differences in technology and trial design suggest distinct paths for each product. Q: Was there any delay in the DV testing for the Selecttra 5 PSP device, and how does it impact the BLA submission timeline? A: Dr. Jackie Shea confirmed that while the DV testing involved multiple external vendors and was complex, the overall timeline for the BLA submission remains on track for the second half of the year, with file acceptance expected by year-end. Q: What is the strategy for a redosing approach for INO 3,107 based on recent data? A: Dr. Mike Sumner explained that Inovio plans to implement a redosing strategy, likely involving annual dosing, to enhance the clinical effect and maintain the reduction in surgeries for RRP patients. This approach leverages the strengths of their DNA medicine platform. Q: How does Inovio plan to address potential enrollment challenges for the confirmatory trial if a competitor's product is approved? A: Dr. Mike Sumner noted that the trial is designed to recruit 100 patients across 20 sites in the U.S., and despite potential market competition, there remains a sizable population of patients who may not have immediate access to the competitor's product due to insurance coverage and other factors. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store